Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL290041 | 0.80 | — | — | |
| SCHEMBL1608761 | 0.79 | ALDH1A1 (0.40) | POLBCYP2C19 | |
| SCHEMBL532324 | 0.77 | KMT2A (0.36) | — | |
| SCHEMBL15201656 | 0.76 | TRPV4 (0.39) | CHRNB2CHRNA4 | |
| SCHEMBL583753 | 0.76 | DGAT1 (0.33) | POLB | |
| SCHEMBL2346145 | 0.76 | CYP3A4 (0.30) | CYP2C19 | |
| SCHEMBL395314 | 0.76 | KDM4E (0.36) | SMN1; SMN2 | |
| SCHEMBL18579546 | 0.75 | KCNJ1 (0.30) | — | |
| SCHEMBL1502522 | 0.74 | NNMT (0.37) | MAPTRAB9A | |
| SCHEMBL25223257 | 0.74 | MAPT (0.44) | MAPTRAB9APOLBSMN1; SMN2CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109689653-B | For the preparation of 2- (6-nitropyridin-3-yl) -9H-bipyridino [2, 3-b; process for 3 ', 4' -d ] pyrroles | 豪夫迈·罗氏有限公司 | 2022-04-12 | — | — | CN | claimed |
| EP-3510031-B1 | PROCESS FOR PREPARATION OF 2-(6-NITROPYRIDIN-3-YL)-9H-DIPYRIDO[2,3-B;3',4'-D]PYRROLE | HOFFMANN LA ROCHE (CH) | 2020-12-02 | — | — | EP | claimed |
| US-20190300529-A1 | Process for preparation of 2-(6-nitropyridin-3-yl)-9H-dipyrido[2,3-b;3',4'-d]pyrrole | HOFFMANN-LA ROCHE INC. (US) | 2019-10-03 | — | — | US | claimed |
| EP-3510031-A1 | PROCESS FOR PREPARATION OF 2-(6-NITROPYRIDIN-3-YL)-9H-DIPYRIDO[2,3-B;3',4'-D]PYRROLE | H. Hoffnabb-La Roche Ag (CH) | 2019-07-17 | — | — | EP | claimed |
| WO-2018046428-A1 | PROCESS FOR PREPARATION OF 2-(6-NITROPYRIDIN-3-YL)-9H-DIPYRIDO[2,3-B;3',4'-D]PYRROLE | F. HOFFMANN-LA ROCHE AG (CH) | 2018-03-15 | — | — | WO | claimed |
| WO-2025098545-A1 | NUCLEOSIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST CORONAVIRUSES | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V. V. I. (CZ) | 2025-05-15 | — | — | WO | disclosed |
| EP-4553080-A1 | NUCLEOSIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST CORONAVIRUSES | Ustav Organicke Chemie a Biochemie AV CR, v.v.i. (CZ) | 2025-05-14 | — | — | EP | disclosed |
| US-11306093-B2 | Process for preparation of 2-(6-nitropyridin-3-yl)-9H-dipyrido[2,3-b;3′,4′-d]pyrrole | HOFFMANN-LA ROCHE, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| CN-109689653-B | For the preparation of 2- (6-nitropyridin-3-yl) -9H-bipyridino [2, 3-b; process for 3 ', 4' -d ] pyrroles | 豪夫迈·罗氏有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-11058781-B2 | Diazacarbazole derivatives as tau-PET-ligands | HOFFMANN-LA ROCHE INC. | 2021-07-13 | — | — | US | disclosed |
| EP-3510031-B1 | PROCESS FOR PREPARATION OF 2-(6-NITROPYRIDIN-3-YL)-9H-DIPYRIDO[2,3-B;3',4'-D]PYRROLE | HOFFMANN LA ROCHE (CH) | 2020-12-02 | — | — | EP | disclosed |
| US-20190300529-A1 | Process for preparation of 2-(6-nitropyridin-3-yl)-9H-dipyrido[2,3-b;3',4'-d]pyrrole | HOFFMANN-LA ROCHE INC. (US) | 2019-10-03 | — | — | US | disclosed |
| US-20180326099-A1 | DIAZACARBAZOLE DERIVATIVES AS TAU-PET-LIGANDS | HOFFMANN-LA ROCHE INC. (US) | 2018-11-15 | — | — | US | disclosed |
| US-10004817-B2 | Diazacarbazole derivatives as tau-PET-ligands | HOFFMANN-LA ROCHE INC. (US) | 2018-06-26 | — | — | US | disclosed |
| WO-2018046428-A1 | PROCESS FOR PREPARATION OF 2-(6-NITROPYRIDIN-3-YL)-9H-DIPYRIDO[2,3-B;3',4'-D]PYRROLE | F. HOFFMANN-LA ROCHE AG (CH) | 2018-03-15 | — | — | WO | disclosed |
| EP-3055308-B1 | DIAZACARBAZOLE DERIVATIVES AS TAU-PET-LIGANDS | HOFFMANN LA ROCHE (CH) | 2017-11-22 | — | — | EP | disclosed |
| EP-3055308-A1 | DIAZACARBAZOLE DERIVATIVES AS TAU-PET-LIGANDS | F.HOFFMANN-LA ROCHE AG (CH) | 2016-08-17 | — | — | EP | disclosed |
| US-20160220712-A1 | DIAZACARBAZOLE DERIVATIVES AS TAU-PET-LIGANDS | HOFFMANN-LA ROCHE INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| WO-2015052105-A1 | DIAZACARBAZOLE DERIVATIVES AS TAU-PET-LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10004817-B2 | Diazacarbazole derivatives as tau-PET-ligands | SNCA, MAPT, PSEN1 | MAPT 2/4885RAB9A 1512/4885POLB 3444/4885 |
| US-20180326099-A1 | DIAZACARBAZOLE DERIVATIVES AS TAU-PET-LIGANDS | SNCA, MAPT, PSEN1 | MAPT 2/4885RAB9A 1512/4885POLB 3444/4885 |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | MAPT 2718/4885RAB9A 1191/4885POLB 4723/4885 |
| US-11058781-B2 | Diazacarbazole derivatives as tau-PET-ligands | SNCA, MAPT, PSEN1 | MAPT 2/4885RAB9A 1512/4885POLB 3444/4885 |
| US-20160220712-A1 | DIAZACARBAZOLE DERIVATIVES AS TAU-PET-LIGANDS | SNCA, MAPT, PSEN1 | MAPT 2/4885RAB9A 1512/4885POLB 3444/4885 |
| US-20190300529-A1 | Process for preparation of 2-(6-nitropyridin-3-yl)-9H-dipyrido[2,3-b;3',4'-d]pyrrole | HBB, PAH, BOLA2; BOLA2B | MAPT 4234/4885RAB9A 514/4885POLB 959/4885 |
| US-11306093-B2 | Process for preparation of 2-(6-nitropyridin-3-yl)-9H-dipyrido[2,3-b;3′,4′-d]pyrrole | HBB, PAH, BOLA2; BOLA2B | MAPT 4237/4885RAB9A 503/4885POLB 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.